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Obstructive Sleep Apnea and Progression of Coronary Artery Calcium:
The Multi-Ethnic Study of Atherosclerosis Study
Younghoon Kwon, MD; Daniel A. Duprez, MD, PhD; David R. Jacobs, Jr, PhD; Mako Nagayoshi, PhD; Robyn L. McClelland, PhD;
Eyal Shahar, MD; Matthew Budoff, MD; Susan Redline, MD; Steven Shea, MD; J. Jeffrey Carr, MD; Pamela L. Lutsey, PhD
Background-—Obstructive sleep apnea (OSA) is a common condition associated with cardiovascular disease. Its potential effect on
progression of subclinical atherosclerosis is not well understood. We tested the hypothesis that self-reported OSA is associated
with progression of coronary artery calcium (CAC). We also evaluated whether traditional cardiovascular risk factors accounted for
the association.
Methods and Results-—In the Multi-Ethnic Study of Atherosclerosis (MESA) prospective cohort, we studied 2603 participants who
at baseline (2002–2004) completed a sleep questionnaire and underwent coronary computed tomography (CT) and, then 8 years
later (2010–2011), a repeat coronary CT. Participants were categorized by symptoms of habitual snoring or reported physician
diagnosis of OSA. At baseline, 102 (3.9%) reported diagnosed OSA; 666 (25.6%) reported diagnosed habitual snoring; and 1835
(70.5%) reported neither habitual snoring nor OSA (“normal”). At baseline, CAC prevalence was highest among those with OSA but
similar for those with and without habitual snoring. During 8 years of follow-up, greater progression of CAC was observed among
those with OSA versus normal (mean increase of 204.2 versus 135.5 Agatston units; P=0.01), after accounting for demographics,
behaviors, and body habitus. Modest attenuation was observed after adjustment for cardiovascular risk factors (188.7 versus
138.8; P=0.06). CAC progression among habitual snorers was similar to that observed in the normal group.
Conclusions-—OSA was associated with CAC score progression after adjustment for demographics, behaviors, and body mass
index. However, the association was not significant after accounting for cardiovascular risk factors, which may mediate the
association between OSA and CAC. ( J Am Heart Assoc. 2014;3:e001241 doi: 10.1161/JAHA.114.001241)
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O bstructive sleep apnea (OSA) is a common condition,estimated to be prevalent in at least 5% to 15% of the
adult population in developed countries.1 Beyond poor quality
of sleep and its directly related symptoms, an emerging body
of evidence links OSA to a more adverse cardiovascular risk
factor profile and increased risk of cardiovascular disease
(CVD) events.2,3 Individuals who snore are known to have a
disproportionately higher prevalence of undiagnosed OSA
compared with those who do not snore,4 and snoring has also
been associated with a higher risk of CVD risk factors and
events.5,6
In an effort to better understand the relation between OSA
and CVD, examining the association between OSA and
subclinical coronary atherosclerotic change may be valuable.7
Coronary artery calcium (CAC) level assessed with the use of
coronary computered tomography (CT) is a well-established
surrogate marker that has been shown in numerous studies to
be predictive of future coronary events.8,9
Results have been inconsistent among the relatively few
studies that have directly explored the association between
OSA and CAC prevalence.10–14 To date, no studies have
assessed the longitudinal association of OSA with change in
CAC. In this study, we tested a hypothesis that during 8 years
of follow-up, participants with OSA would have a more
pronounced increase in CAC, relative to participants who do
not snore, in a racially/ethnically diverse population free of
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overt CVD. We anticipated that participants who self-reported
snoring would have an intermediate increase in CAC. The
cross-sectional association between self-reported OSA and
CAC prevalence is also reported.
Methods
Study Population
The Multi-Ethnic Study of Atherosclerosis (MESA) is a
prospective cohort study of 6814 community-dwelling men
and women aged 45 to 84 years without evidence of CVD at
baseline (2000–2002). Participants were recruited from 6
US communities (Forsyth County, NC; northern Manhattan
and the Bronx, NY; Baltimore County, MD; St. Paul, MN;
Chicago, IL; and Los Angeles County, CA) and self-identified
as white, Chinese, black, or Hispanic.15 A total of 6232
participants attended MESA exam 2 (September 2002–
February 2004), of whom 5395 completed the sleep history
questionnaire. Among those who completed the sleep
questionnaire, 4919 underwent coronary CT at exam 2 or
had coronary CT at both exam 1 (June 2000–August 2002)
and exam 3 (March 2004–September 2005), thereby
allowing us to derive interpolated exam 2 CAC for 50%
of the cohort who did not have coronary CT at exam 2.
These participants made up our “parent cohort.” We required
that for the main analysis of CAC change, participants also
attend a coronary CT exam at MESA visit 5 (April 2010–
December 2011; attended by 55% of the parent cohort).
After excluding participants with a history of revasculariza-
tion and 1 participant with apparent CAC measurement
error, our final analytic sample included 2603 participants
(“final cohort”). The research protocols were approved by
the institutional review board at each participating institu-
tion, and all participants gave written informed consent.
Detailed descriptions of the study design and methods of
MESA have been published previously.15
Sleep Disordered Breathing History
A self-administered sleep history questionnaire conducted at
exam 2 was used to construct 3 sleep disordered breathing
(SDB) groups (OSA, habitual snoring, normal) using the
algorithm illustrated in Figure 1. Because OSA (versus central
sleep apnea) is by far the most common form of sleep apnea
in the absence of heart failure or stroke, we considered self-
reported physician-diagnosed sleep apnea to be OSA in this
study. In addition, information on perception of excessive
daytime sleepiness was extracted from the question: How
often do you feel excessively (overly) sleepy during the day?
(Those who responded “often” [5 to 15 days/month] or
“almost always” [16 to 30 days/month] were considered to
have excessive daytime sleepiness.) This information was
used to test for potential effect modification.
CAC Scores
Details of the technique and methodology of the scans and
approach to quantifying CAC have been previously pub-
lished.16 CAC scores were quantified by using the Agatston
method17 from 2 consecutively obtained CT scans at each
visit, and average CAC scores were obtained. CAC scores
were subsequently adjusted with a standard calcium phantom
that was scanned along with the participant.16 Interobserver
and intraobserver agreements were high (j statistics=0.93
and 0.90, respectively).18
The absolute difference in CAC score between MESA
exam 2 (when the sleep survey took place) and exam 5 was
used as our primary end point, representing change in CAC
during an average of 8 years. By design, only 50% of the
MESA sample underwent CT at exam 2. For those without
available CT at exam 2, interpolated CAC was derived by
averaging the CAC scores of exams 1 and 3, assuming a
linear rate of change in CAC. Because approximately half of
the participants who underwent exam 1 CT were randomly
allocated to have a follow-up CT at either exam 2 or 3 but
not both, there was no overlap between the cohorts who
underwent CT at exam 2 and exam 3. Notably, only one-
quarter of the full MESA cohort underwent CAC scans at
exam 4 (September 2005–May 2007); to maximize the size
of cohort and the time interval over which CAC progression
Figure 1. Algorithm for defining sleep disordered breathing
history groups: MESA. Construction of 3 sleep breathing disorder
history groups based on the self-administered sleep history
questionnaire in final cohort (n=2603), based on the following
questions: (A) (Physician-diagnosed sleep apnea question); Have
you ever been told by a doctor that you had sleep apnea? (B)
(Snoring question) Have you ever snored (now or at any time in
the past)? (C) (Snoring frequency question) How often do you
snore now? Snoring frequency response definitions: sometimes:
snoring up to 2 nights a week; frequently: snoring 3 to 5 nights a
week; always or almost always: snoring 6 to 7 nights a week.
MESA indicates Multi-Ethnic Study of Atherosclerosis; OSA,
obstructive sleep apnea.
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might occur, exam 5 CAC was chosen for calculating CAC
change instead of exam 4 CAC.
Covariates
Information on demographics, smoking, physical activity, and
medical conditions were obtained via questionnaire at exam
2. Smoking status was categorized as never, former, or
current smoker. Physical activity was determined by calcula-
tion of weekly MET-minute of total walking, conditioning, and
sports activity. Body mass index (BMI) obtained at exam 2
were categorized into normal (BMI <25 kg/m2), overweight
(25≤BMI<30 kg/m2), and obese (BMI ≥30 kg/m2). Use of
diabetes, hypertension, and cholesterol medications was
determined via questionnaire and from medication containers
that were brought to the exam 2 clinic visit. Blood samples
collected after a 12-hour fast were used to determine fasting
glucose level, and low- and high-density lipoprotein choles-
terol (LDL-C and HDL-C, respectively). Diabetes was defined
as a fasting glucose level of ≥7.0 mmol/L (126 mg/dL) or
use of insulin or oral hypoglycemic medications. Hypertension
was determined if seated systolic blood pressure was ≥140
mm Hg and/or diastolic blood pressure was ≥90 mm Hg.
Statistical Analysis
Characteristics of participants were compared based on the
self-reported SDB history, the main exposure predictor of
interest (ie, normal, habitual snoring, and OSA), using v2 test
or 1-way ANOVA for categorical and continuous variables,
respectively. Mean (SD) and percentage were used to
describe continuous and categorical variables, as appropriate.
Mean absolute CAC score and prevalence for CAC (CAC
score >0 [ie, presence of CAC]) and CAC 400 (CAC score
>400 [ie, high burden of CAC]) in the final cohort at baseline
were compared according to SDB history characteristics using
Kruskal–Wallis tests (with pairwise post-hoc Wilcoxon test)
and v2 tests, respectively.
For multivariable comparison of the prevalence rates,
Poisson regression with a robust error variance19 was used,
with adjustment using the following nested models: model 1
included age, sex race/ethnicity, education level, site, smok-
ing, and physical activity; model 2 included model 1 plus BMI
category; and model 3 included model 2 plus several markers
of potential intermediate variables in the pathway between
OSA and CAC change (ie, prevalent diabetes, seated systolic
blood pressure, HDL-C, LDL-C, and antihypertensive and lipid-
lowering medication).
The main outcome of interest, absolute CAC change
continuously measured was determined by subtracting CAC
score at exam 2 (measured or interpolated) from that at exam
5. Multiple linear regression was performed to calculate the
mean CAC change between the SDB groups. The same
covariates were used as for the baseline prevalence compar-
ison. Because there are several different approaches to
analyzing change,20 as a sensitivity analysis, we modeled
change with absolute CAC at exam 5 as the dependent
variable, without considering baseline CAC values. Possible
effect modification of associations between SDB and CAC
change by age, sex, race, BMI category, and reported
excessive daytime sleepiness was tested by including cross-
product terms in the models. A P value <0.05 was considered
significant. Sensitivity analysis was also performed after
excluding participants with negative CAC change, which may
represent measurement error. All statistical analyses were
performed using SAS version 9.3 (SAS Institute).
Results
A total of 2603 participants were eligible for the main analysis
evaluating change in CAC score between exams 2 and 5. This
final cohort included 102 (3.9%) participants with OSA, 666
(25.6%) with habitual snoring, and 1835 (70.5%) without a
history of habitual snoring or OSA (normal). This distribution
was similar to the parent cohort (n=4919, OSA: n=3464
[70.4%], habitual snoring: n=1261 [25.6%], normal: n=194
[3.9%]).
The baseline characteristics are shown in Table 1. Partic-
ipants with OSA, compared with those without OSA, were
more likely to be white, male, have higher incomes and
educational attainment, be obese, have prevalent diabetes,
and be on medication for hypertension and hyperlipidemia.
Levels of both HDL and LDL were lower among the OSA
group; however, after restricting the analysis to participants
not taking lipid-lowering medications, LDL levels were similar
across SDB categories. Overall, characteristics of the habitual
snoring group were similar to those of the normal group. More
than a third of participants with OSA (38.6%) reported having
excessive daytime sleepiness compared with 27.9% and
18.5% in the habitual snoring and normal groups, respectively
(P<0.0001). Unadjusted baseline CAC score and CAC prev-
alence were significantly different across the groups
(Table 1).
Prevalence of CAC at Baseline From Parent
Cohort (n=4919)
At baseline, the overall prevalence of positive CAC (CAC >0)
was high in all groups but was highest in the OSA group (OSA:
64.4%; habitual snoring: 55.0%; normal: 55.6%, P=0.04). The
prevalence of high CAC burden (CAC >400) showed a similar
pattern (OSA: 19.1%, habitual snoring: 10.4%, normal: 12.0%,
P=0.002). In multivariable analyses, for CAC >0 the association
DOI: 10.1161/JAHA.114.001241 Journal of the American Heart Association 3
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Table 1. Characteristics of the Participants in Final Cohort by Self-Reported Sleep Disordered Breathing History (n=2603): MESA
Variables Normal (n=1835) Habitual Snoring (n=666) OSA (n=102) P Value
Demographics
Age (y), mean (SD) [range] 61.8a (9.4) [46 to 86] 59.6b (8.6) [46 to 83] 59.5b (8.6) [46 to 81] <0.0001
Male, n (%) 796 (43.4) 401 (60.2) 76 (74.5) <0.0001
Race, n (%) 0.002
White, Caucasian 739 (40.3) 234 (35.1) 48 (47.1)
Chinese American 203 (11.1) 97 (14.6) 7 (6.9)
Black, African American 504 (27.5) 162 (24.3) 30 (29.4)
Hispanic 389 (21.2) 173 (26.0) 17 (16.7)
Education, n (%) 0.0499
<High school degree 226 (12.3) 100 (15.0) 6 (5.9)
High school degree or some college 883 (48.2) 300 (45.1) 47 (46.1)
College graduate 725 (39.5) 265 (39.9) 49 (48.0)
Income, n (%) 0.003
<$20 000 328 (18.5) 112 (17.3) 8 (8.0)
$20 000 to $50 000 679 (38.3) 233 (36.0) 30 (30.0)
>$50 000 767 (43.2) 302 (46.7) 62 (62.0)
Lifestyle
Smoking, n (%) 0.09
Never 889 (48.7) 288 (43.7) 39 (38.6)
Former 754 (41.3) 295 (44.8) 49 (48.5)
Current 184 (10.1) 76 (11.5) 13 (12.9)
Physiologic characteristics
BMI category (kg/m2), n (%) <.0001
<25 530 (28.9) 137 (20.6) 9 (8.8)
25 to 30 775 (42.3) 254 (38.1) 36 (35.3)
≥30 529 (28.8) 275 (41.3) 57 (55.9)
Comorbidities
Prevalent diabetes, n (%) 209 (11.5) 101 (15.3) 21 (20.8) 0.002
Prevalent hypertension, n (%) 737 (40.6) 285 (43.3) 48 (47.5) 0.2
Hypertension medication, n (%) 655 (37.3) 270 (42.7) 47 (47.5) 0.01
SBP (mm Hg) mean (SD) [range] 122.1a (19.7) [73 to 202] 124.1b (18.9) [85.5 to 216] 120.8ab (16.9) [87.5-170.5] 0.046
HDL cholesterol (mg/dL) mean (SD) [range] 52.9a (15.2) [21 to 161] 48.0b (12.4) [24 to 111] 46.8b (10.5) [24 to 77] <.0001
LDL cholesterol (mg/dL) mean (SD) [range] 113.0a (31.0) [21 to 243] 117.0b (30.3) [41 to 281] 104.3c (30.1) [34 to 178] <.0001
Lipid-lowering medications, n (%) 380 (21.7) 75 (20.9) 31 (31.3) 0.07
Baseline CAC
CAC score mean* (median) [range] 108.5a (0) [0 to 4744.1] 108.6a (1.2) [0 to 2963.9] 163.2b (19.3) [0 to 1175.5] 0.0006
Prevalence CAC >0, n (%) 900 (49.1) 347 (52.1) 66 (64.7) 0.005
Prevalence CAC >400, n (%) 132 (7.2) 48 (7.2) 17 (16.7) 0.002
For continuous variables, values without sharing common alphabet letters denote significant difference. MESA, Multi-Ethnic Study of Atherosclerosis; OSA, obstructive sleep apnea;
BMI, body mass index; SBP, systolic blood pressure; HDL, high-density lipoprotein; LDL, low-density lipoprotein; CAC, coronary artery calcium.
*Kruskal–Wallis test with pairwise post-hoc Wilcoxon test was used.
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was no longer present when adjusted for BMI (Table 2A). For
CAC >400, the association persisted after adjustment for BMI
and CVD risk factors (Table 2B). For both CAC >0 and CAC
>400, the habitual snoring group behaved similar to the normal
group.
Longitudinal Change in CAC (n=2603)
During 8 years of follow-up, CAC change in the final cohort
ranged from 362 to 3261, and its mean and median were
140.4 and 25.9, respectively. Unadjusted change in CAC was
significantly more pronounced in the OSA group compared
with normal or habitual snoring groups (Agatston units mean
[95% CI] OSA: 227.7 [173.3 to 282.1]; habitual snoring: 140.4
[119.1 to 161.6], normal: 135.6 [95% CI: 122.8 to 148.4]).
The pattern persisted in multivariable analysis adjusting for
baseline demographic, life style factors (model 1), and BMI
(model 2, OSA: 204.2 [152.8 to 255.5]; habitual snoring:
132.6 [112.2 to 153.0], normal: 135.5 [123.3 to 147.6])
(Table 3). Figure 2 shows CAC scores at visit 2 and at visit 5,
stratified by SDB category, with model 2 adjustments. With
further adjustment for CVD risk factors (model 3), the
association between OSA and the normal group was modestly
attenuated and no longer significant (P=0.06). In sensitivity
analyses modeling CAC at exam 5 (the follow-up CAC) without
taking into account baseline CAC, the results were slightly
attenuated (Table 4). At exam 5, the prevalence of CAC >0
was 67.6%, 70.3%, and 73.5 for the no snoring, habitual
snoring, and OSA groups, respectively (P=0.24).
Effect modification was not present by age, sex, BMI
category, or excessive daytime sleepiness but was present by
race. Subsequent stratified analysis showed that in blacks, no
difference in CAC change was observed across the groups.
This result should be viewed cautiously, however, given the
number of comparisons and the limited sample size for race-
specific analyses.
In alternative analyses, when the OSA group was compared
with combined “no OSA group” (habitual snoring+normal
group), the OSA group experienced a significantly greater
increase in CAC score, regardless of degree of adjustment
(Table 5). Because negative change in CAC might be due to
measurement error rather than a true regression, we
Table 2. Prevalence Ratio of Positive CAC at Baseline in Parent Cohort by Sleep Disordered Breathing History (n=4919): MESA
Habitual Snoring vs Normal OSA vs Habitual Snoring OSA vs Normal
PR 95% CI P Value PR 95% CI P Value PR 95% CI P Value
A: CAC >0
Model 1 1.05 0.99 to 1.11 0.1 1.11 1.00 to 1.23 0.05 1.16 1.06 to 1.29 0.002
Model 2 1.02 0.96 to 1.08 0.6 1.07 0.96 to 1.19 0.2 1.08 0.98 to 1.20 0.1
Model 3 1.02 0.97 to 1.08 0.4 1.03 0.93 to 1.16 0.5 1.06 0.96 to 1.18 0.3
B: CAC >400
Model 1 1.09 0.90 to 1.31 0.4 1.51 1.11 to 2.06 0.009 1.64 1.24 to 2.17 0.0005
Model 2 1.02 0.84 to 1.24 0.8 1.38 1.01 to 1.88 0.04 1.41 1.06 to 1.87 0.02
Model 3 1.05 0.87 to 1.27 0.6 1.33 0.97 to 1.81 0.08 1.40 1.05 to 1.86 0.02
Model 1 adjusted for age, race, sex, site, income level, educational level, smoking status, and physical activity level (n=4703). Model 2 adjusted for model 2 plus BMI category (n=4702).
Model 3 adjusted for model 2 plus diabetes, systolic blood pressure, hypertension medication, and LDL, HDL, and cholesterol medication (n=4401). CAC indicates coronary artery calcium;
MESA, Multi-Ethnic Study of Atherosclerosis; PR, prevalence ratio; OSA, obstructive sleep apnea; BMI, body mass index; HDL, high-density lipoprotein; LDL, low-density lipoprotein.
Table 3. Comparison of Absolute CAC Score Change Over 8 Years of Follow-up by Sleep Disordered Breathing History in Final
Cohort (n=2603): MESA
Normal (n=1835) Habitual Snoring (n=666) OSA (n=102)
Habitual Snoring
vs Normal
OSA vs Habitual
Snoring
OSA vs
Normal
Mean 95% CI Mean 95% CI Mean 95% CI P Value
Model 1 132.3 120.1 to 144.4 138.9 118.5 to 159.3 220.6 169.2 to 272.0 0.6 0.004 0.001
Model 2 135.5 123.3 to 147.6 132.6 112.2 to 153.0 204.2 152.8 to 255.5 0.8 0.01 0.01
Model 3 138.8 126.8 to 150.8 127.6 107.2 to 148.0 188.7 137.7 to 239.6 0.4 0.03 0.06
Model 1 adjusted for age, race, sex, site, income level, educational, smoking status, and physical activity level (n=2502). Model 2 adjusted for model 1 plus BMI category (n=2501). Model
3 adjusted for model 2 plus diabetes, systolic blood pressure, hypertension medication, and LDL, HDL, and cholesterol medication (n=2344). CAC indicates coronary artery calcium; MESA,
Multi-Ethnic Study of Atherosclerosis; OSA, obstructive sleep apnea; BMI, body mass index; HDL, high-density lipoprotein; LDL, low-density lipoprotein.
DOI: 10.1161/JAHA.114.001241 Journal of the American Heart Association 5
OSA and CAC Progression Kwon et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
performed analysis by excluding subjects (6%) with any
negative change. The results were similar before and after the
exclusion (data not shown). Finally because CAC change did
not exhibit normally distributed pattern owing to large portion
of cohort without significant change, we also performed the
analysis using log-transformed CAC change. However, results
were largely unchanged (data not shown).
Discussion
In this large racially and ethnically diverse cohort without
evidence of CVD at baseline, we found that having OSA
based on self-reported physician diagnosis versus being a
habitual snorer or reporting a normal SDB pattern was
associated with a greater progression of CAC, as measured
by absolute change in CAC scores over an average of
8 years. These associations remained significant even after
adjusting for BMI but were modestly attenuated after
additionally accounting for key CVD risk factors, such as
hypertension, diabetes, and hyperlipidemia. Although this
attenuation may reflect confounding, current etiological
understanding suggests that these traditional CVD risk
factors may mediate the association between OSA and CAC
progression.
Indeed OSA has been linked to the development of
these cardiovascular risk factors,21,22 and these risk factors
have been associated with CAC incidence and progres-
sion.23 Perhaps the strongest evidence exists for hyperten-
sion. In observational data, a dose–response association
has been observed between SDB and incidence of hyper-
tension,22 and randomized controlled trials of OSA patients
have demonstrated improved blood pressure after treat-
ment with continuous positive airway pressure.24,25
Relatively few cross-sectional studies have explored the
association between OSA and CAC prevalence, and they have
yielded conflicting results, in both clinical and population-
based settings. One clinic-based study of patients who were
referred for both a sleep study and coronary CT showed a
significantly higher prevalence of positive CAC and a higher
CAC score in patients with OSA in a dose-dependent manner
according to the severity.13 Such a finding, however, was not
replicated in a similarly designed clinic-based study.12 One
population-based study showed an independent linear asso-
ciation of OSA severity with CAC score in women of all ages
and in men <65 years old.11 To the contrary, other studies
involving a community cohort failed to show a significant
independent association between OSA and prevalence or
burden of CAC after adjusting for BMI.10,14 Likewise, in the
present study, the association between OSA and presence of
CAC >0 at baseline was not significant after adjusting for BMI.
When CAC >400 was considered, however, the association
did persist after accounting for BMI, as well as traditional CVD
risk factors.
A major advantage of our analysis over prior work is the
prospective design, assessing the relation of OSA and CAC
Table 4. Absolute CAC Score at Exam 5 Without Accounting for Baseline CAC Values by Sleep Disordered Breathing Category in
Final Cohort (n=2603): MESA
Normal (n=1835) Habitual Snoring (n=666) OSA (n=102)
Habitual Snoring
vs Normal
OSA vs Habitual
Snoring
OSA vs
Normal
Mean 95% CI Mean 95% CI Mean 95% CI P Value
Model 1 238.5 214.9 to 262.1 251.7 212.2 to 291.3 365.6 265.9 to 465.3 0.6 0.04 0.02
Model 2 242.5 218.9 to 266.1 243.9 204.2 to 283.5 345.5 245.5 to 445.5 1.0 0.06 0.051
Model 3 250.7 226.6 to 274.8 239.3 198.5 to 280.2 316.9 214.8 to 419.0 0.6 0.2 0.2
Model 1 adjusted for age, race, sex, site, income level, educational, smoking status, and physical activity level (n=2502). Model 2 adjusted for model 1 plus BMI category (n=2501). Model
3 adjusted for model 2 plus diabetes, systolic blood pressure, hypertension medication, and LDL, HDL, and cholesterol medication (n=2344). BMI indicates body mass index; CAC, coronary
artery calcium; MESA, Multi-Ethnic Study of Atherosclerosis; OSA, obstructive sleep apnea; HDL, high-density lipoprotein; LDL, low-density lipoprotein.
Figure 2. CAC progression during an 8-year period: MESA.
Adjusted* absolute CAC scores (mean and 95% CI) and CAC
progression over 8 year period stratified by sleep disordered
breathing history. *Model 2 adjusted for age, race, sex, site,
income level, educational, smoking status, physical activity level,
and BMI category (n=2501). P values comparing CAC change
between the groups. OSA vs normal: 0.01; OSA vs habitual
snoring: 0.01; habitual snoring vs normal: 0.8. BMI indicates body
mass index; CAC, coronary artery calcium; MESA indicates Multi-
Ethnic Study of Atherosclerosis; OSA, obstructive sleep apnea.
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change over 8 years of follow-up. While baseline CAC score
offers independent incremental information over and above
traditional risk factors in the prediction of all-cause mortal-
ity,26 progression of CAC has been shown to further increase
the risk for coronary heart disease events in the MESA
cohort.27 Also within MESA, self-reported OSA was found to
be predictive of increased risk of incident CVD events and all-
cause mortality.28 Since OSA is considered a treatable
condition, this provides an important basis for future studies
evaluating the treatment of OSA on the development and
progression of cardiovascular risk factors, which may mediate
the association between OSA and CAC progression.
Given that people who habitually snore are more likely to
have undiagnosed OSA4 and the body of evidence relating
habitual snoring to cardiovascular morbidities, we hypothe-
sized that those reporting “habitual snoring” would have
greater CAC progression than those reporting no snoring
(“normal” group). However, our analysis showed that, overall,
CAC progression in the habitual snoring group was similar to
that of the normal group. Habitual snoring likely identifies
individuals with a very wide range of OSA severity, including
individuals with snoring without significant airflow limitation
to those with frequent apnea, hypopnea, and oxyhemoglobin
desaturation. The stronger finding with self-reported physi-
cian-diagnosed OSA, which likely identifies the more severely
affected (and hypoxemic individuals), provides support to the
notion that intermittent hypoxemia contributes to the path-
ogenesis of atherosclerosis as measured by CAC progression.
Although the underlying mechanism of OSA’s effect on CAC
progression is uncertain, it likely acts through repetitive
airway obstruction and intermittent hypoxemia resulting in
endothelial dysfunction29 and inflammation30,31 via oxidative
stress32 or heightened sympathetic activity.33 Through these
mechanisms, OSA may exert its deleterious effect on the
progression of subclinical atherosclerosis either directly or
indirectly via mediators such as hypertension,34 diabetes,35
and metabolic syndrome,36 which can all lead to hard CVD
events such as coronary heart disease, stroke, and heart
failure as shown in recent prospective studies.3,37 Although
not feasible in this study, relating our findings to simulta-
neously obtained biomarkers of endothelial dysfunction or
inflammation will provide valuable insights into the underlying
mechanism. Key strengths of this study are the prospective
design that included an average of 8 years of follow-up,
objectively measured CAC, and a diverse study sample. A
limitation of our study is the relatively small number of
participants with OSA, which at times resulted in wide
confidence intervals and perhaps imprecise estimates. OSA is
known to be underdiagnosed in the community, particularly as
many individuals with OSA lack classic symptoms.38 Because
in our sample diagnosis of OSA relied solely on self-reported
history but not on the objective measurement, the prevalence
of OSA (4%) reported in our study is almost certainly an
underestimate. The resultant misclassification may have
biased our results toward the null. Conversely, the partici-
pants with OSA in our study may represent highly symptom-
atic individuals with more severe OSA, thus possibly biasing
our results away from the null. Likelihood of receiving an OSA
diagnosis may also have been dependent on the access to
health care; in our sample those self-reporting OSA tended to
have higher incomes and greater educational attainment. In
addition, it is possible that a number of participants in the
OSA group may have been receiving treatment for OSA, which
may have weakened the association, though to date there is
no supporting evidence of a beneficial effect of therapy on the
progression of CAC. However, a graded relationship has been
noted between adherence to OSA treatment using continuous
positive airway pressure and total mortality.39 Residual
confounding resulting from unmeasured confounders in our
hypothesized casual model or imprecisely measured covari-
ates should be also considered. Finally, several caveats need
to be explained in regard to the methodology of quantifying
and analyzing CAC progression in our study. First, we
observed negative CAC change in varying degrees in a small
number of subjects (6% of the final cohort). This likely
represents measurement error, though true regression of
coronary calcification is not impossible. Analysis removing
participants with negative CAC progression did not change
the results. Second, the absolute CAC score used to measure
progression in our study can introduce an overestimation of
Table 5. Comparison of Absolute CAC Score Change Based on the Presence of OSA in Final Cohort (n=2603): MESA
No OSA (n=2501) OSA (n=102)
P ValueMean CI Mean CI
Model 1 134.0 123.7 to 144.4 220.3 169.0 to 271.7 0.001
Model 2 134.7 124.4 to 145.0 204.3 153.0 to 255.7 0.009
Model 3 135.8 125.7 to 146.0 189.3 138.4 to 240.3 0.04
Model 1 adjusted for age, race, sex, site, income level, educational, smoking status, and physical activity level (n=2502). Model 2 adjusted for model 1 plus BMI category (n=2501). Model
3 adjusted for model 2 plus diabetes, systolic blood pressure, hypertension medication, and LDL, HDL, and cholesterol medication (n=2344). CAC indicates coronary artery calcium; OSA,
obstructive sleep apnea; MESA, Multi-Ethnic Study of Atherosclerosis; BMI, body mass index.
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the actual progression of CAC in subjects with higher baseline
CAC compared with those with low baseline CAC due to
higher interscan variability.40 Third, to enhance power,
interpolated data based on an assumption of linear progres-
sion was used to estimate baseline CAC in approximately half
of the cohort (those who had CAC measurement at exams 1
and 3 but not exam 2). Because our focus was on the absolute
CAC change rather than an incidence of CAC, we believe
interpolation was an acceptable approach.
In summary, in this large and racially/ethnically diverse
cohort, participants who self-reported physician diagnosis of
OSA experienced greater CAC progression during 8 years of
follow-up, relative to those who were habitual snoring or
reported a normal SDB pattern. CAC progression was similar
among participants who reported habitual snoring and those
classified as normal. Furthermore, despite being free of
clinical CVD at baseline, individuals with OSA had higher
levels of severe CAC at baseline. Our finding that participants
with OSA experienced greater CAC progression provides an
important rationale for further studies focusing on the effect
of objectively measured OSA on the development of cardio-
vascular risk factors and subclinical cardiovascular disease.
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